Dr. Simpson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6560 Fannin St
Suite 802
Houston, TX 77030Phone+1 713-441-3780
Education & Training
- Baylor College of MedicineResidency, Neurology, 1996 - 1999
- Baylor College of MedicineInternship, Internal Medicine, 1995 - 1996
- McGovern Medical School at UTHealthClass of 1995
Certifications & Licensure
- TX State Medical License 1997 - 2026
- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Clinical Trials
- Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD) Start of enrollment: 2009 Jul 01
- Gilenya in Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- 35 citationsA randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.Mamatha Pasnoor, Jianghua He, Laura Herbelin, Ted M Burns, Sharon Nations
Neurology. 2016-07-05 - 443 citationsAn antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man studyTimothy M. Miller, Alan Pestronk, William S. David, Jeffrey D. Rothstein, Ericka Simpson
The Lancet. Neurology. 2013-05-01 - 97 citationsDistinctive genetic and clinical features of CMT4J: a severe neuropathy caused by mutations in the PI(3,5)P2 phosphatase FIG4Garth A. Nicholson, Guy M. Lenk, Stephen W. Reddel, Adrienne E. Grant, Charles F. Towne
Brain. 2011-07-01
Press Mentions
- Neurology Questions? Ask the Experts at Houston Methodist Q&A SessionOctober 16th, 2018
- Stem Cells Deemed Safe for ALS PatientsJune 29th, 2016
- New ALS Drug Headed for Phase II TrialOctober 25th, 2013
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: